Tau reduction affects excitatory and inhibitory neurons differently, reduces excitation/inhibition ratios, and counteracts network hypersynchrony
- PMID: 34686344
- PMCID: PMC8648275
- DOI: 10.1016/j.celrep.2021.109855
Tau reduction affects excitatory and inhibitory neurons differently, reduces excitation/inhibition ratios, and counteracts network hypersynchrony
Abstract
The protein tau has been implicated in many brain disorders. In animal models, tau reduction suppresses epileptogenesis of diverse causes and ameliorates synaptic and behavioral abnormalities in various conditions associated with excessive excitation-inhibition (E/I) ratios. However, the underlying mechanisms are unknown. Global genetic ablation of tau in mice reduces the action potential (AP) firing and E/I ratio of pyramidal cells in acute cortical slices without affecting the excitability of these cells. Tau ablation reduces the excitatory inputs to inhibitory neurons, increases the excitability of these cells, and structurally alters their axon initial segments (AISs). In primary neuronal cultures subjected to prolonged overstimulation, tau ablation diminishes the homeostatic response of AISs in inhibitory neurons, promotes inhibition, and suppresses hypersynchrony. Together, these differential alterations in excitatory and inhibitory neurons help explain how tau reduction prevents network hypersynchrony and counteracts brain disorders causing abnormally increased E/I ratios.
Keywords: Alzheimer’s disease; axon initial segment; epilepsy; excitation-inhibition balance; hypersynchrony; interneurons; intrinsic excitability; neuronal plasticity; pyramidal cells; tau.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests L.M. has received research funding from Cure Network Dolby Acceleration Partners (CNDAP) and has served on CNDAP’s board of managers. He has also served on the scientific advisory boards of Arvinas, Biogen, and Dolby Family Ventures and has consulted for Eisai and Sangamo Therapeutics. L.M. is a coinventor on patents held by the Gladstone Institutes that focus on tau reduction as a strategy to block neural network dysfunction.
Figures
References
-
- Bender KJ, and Trussell LO (2012). The physiology of the axon initial segment. Annu. Rev. Neurosci 35, 249–265. - PubMed
-
- Booker SA, Simões de Oliveira L, Anstey NJ, Kozic Z, Dando OR, Jackson AD, Baxter PS, Isom LL, Sherman DL, Hardingham GE, et al. (2020). Input-output relationship of CA1 pyramidal neurons reveals intact homeostatic mechanisms in a mouse model of fragile x syndrome. Cell Rep. 32, 107988. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
